Purchase this article with an account.
Charles Wykoff, David Brown, Daniel Croft, RAVE Study Group; Peripheral Retinal Perfusion and Functional Analysis of Patients with Ischemic Central Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1156. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Progressive retinal perfusion and peripheral visual field (VF) changes in eyes with central retinal vein occlusions (CRVO) are incompletely understood. Our purpose was to quantify long-term trends in capillary non-perfusion and VF patterns in patients with ischemic CRVO treated with ranibizumab over 36 months.
Wide-field fluorescein angiography (FA) and Goldmann VF (GVF) were performed serially in patients with ischemic CRVO who were treated in the 36-month prospective Rubeosis Anti-VEGF (RAVE) trial evaluating intravitreal ranibizumab. All patients received ranibizumab injections for 9 months followed by pro re nata ranibizumab in months 12-36. Serial wide-field FA was performed with a Heidelberg Spectralis HRA utilizing the Staurenghi contact lens. Areas of perfusion/non-perfusion were graded by masked graders and pixels quantified. GVF were assessed every 6 months and changes in the I-4e isopter were analyzed.
Twelve patients had sequential wide-field FA for 36 months. At baseline, mean perfusion was 36.7% (106.4 disc areas) of the gradable field (mean: 290 disc areas, range 178-452). The area of non-perfusion increased in all patients with a mean loss of approximately 5% of retina area (loss of 14.5 mean disc areas of perfusion) per 6 month period. In comparison to progressive loss of perfusion, 3 patterns of GVF progression were identified: early loss (n=6), early gain with late loss (n=3), and stability (n=3). Progressive non-perfusion and changes in GVF were most pronounced in the first year of the trial. Despite capillary and GVF losses, vision improved in these eyes from a baseline of 23.1 best corrected Early Treatment Diabetic Retinopathy Study (ETDRS) letters to 30.5 ETDRS letters (mean gain: +7.4 letters) at month 36.
In this prospective CRVO trial, progressive capillary loss was quantified. Similarly, peripheral visual field loss as measured by GVF progressed in most eyes (n=9). Changes in perfusion and GVF were particularly evident in the first year of treatment. Despite perfusion and GVF losses in many patients, vision improved, as the majority of these anatomic and functional changes were peripheral.
This PDF is available to Subscribers Only